CTLA4 and hepatocellular carcinoma: Thus, a series of clinical trials evaluating the efficacy and safety of PD-1-CTLA-4 BsAb as monotherapy (NCT04728321) or in combination with lenvatinib (NCT04444167), regorafenib (NCT05773105) and TACE (NCT05925413) are currently underway for the treatment of advanced HCC.